Literature DB >> 19246116

Analysis of HLA class I and II alleles regarding to lymph node and distant metastasis in patients with non-small cell lung cancer.

Ismet Bulut1, Mehmet Meral, Hasan Kaynar, Ibrahim Pirim, Mehmet Bilici, Metin Gorguner.   

Abstract

The aim of this study was to investigate the relation of HLA alleles in patients with non-small cell lung cancer (NSCLC). The incidence of class I and II HLA alleles of 63 patients with NSCLC were prospectively compared with the incidence of class I and II HLA alleles with 88 healthy controls. The number of cases with stage I and II (early stage) was 12 and there were 51 cases with stage III and IV (advanced stage). Metastasis rates of the regional lymph node in patients were as follow; N(0): n=10; N(1): n=13; N(2): n=26 and N(3): n=14. Lymph node metastasis was detected by pathological staging in 15 cases and by clinical staging in 48 cases. Lymph node metastasis was searched in all patients by a helical thorax CT. All distant metastasis were investigated by thorax CT, abdominal CT, brain CT or MRI and bone scintigraphy, and distant organ metastasis was detected in 25 cases. The patients and healthy controls were typed for HLA class I and II alleles. HLA-A2 was an independent risk factor for both critical lymph node (N(2 and 3)) involvement and distant metastasis. HLA-B44, -CW6 and -CW7 frequencies appear to be significant in controls compared to patients. HLA-A2 frequency was higher in patients with advanced stage than early stage, while HLA-A26, -B35 and -CW4 frequencies were more expressed in patients with early stage than in patients with advanced stage. Compared with controls, frequency of HLA-DRB1*07, -DQ02 and -DQ07 were lower expressed in patients. Compared patients with advanced stage, HLA-DRB1*07 was higher in patients with early stage. HLA-A2 was an independent risk factor for lymph node and distant metastasis, and the allele was significantly higher in patients with critical lymph node for surgery and distant metastasis. HLA-A26 appeared to be a significance protective allele against to metastases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19246116     DOI: 10.1016/j.lungcan.2009.01.012

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  6 in total

1.  Associations of Human Leukocyte Antigen-DRB1 Alleles with Nasopharyngeal Carcinoma and Its Clinical Significance in Xinjiang Uyghur Autonomous Region of China.

Authors:  Xiao-Tao Geng; Yun-Hui Hu; Tao Dong; Ruo-Zheng Wang
Journal:  Chin Med J (Engl)       Date:  2016-06-05       Impact factor: 2.628

2.  Tumor mutation burden and recurrent tumors in hereditary lung cancer.

Authors:  Yi-Chiung Hsu; Ya-Hsuan Chang; Gee-Chen Chang; Bing-Ching Ho; Shin-Sheng Yuan; Yu-Cheng Li; Jhih-Wun Zeng; Sung-Liang Yu; Ker-Chau Li; Pan-Chyr Yang; Hsuan-Yu Chen
Journal:  Cancer Med       Date:  2019-04-02       Impact factor: 4.452

3.  The association of HLA/KIR genes with non-small cell lung cancer (adenocarcinoma) in a Han Chinese population.

Authors:  Yingfu Li; Shuyuan Liu; Chao Hong; Qianli Ma; Fang Tan; Chengxiu Liu; Piotr Kuśnierczyk; Chuanyin Li; Li Shi; Yufeng Yao
Journal:  J Cancer       Date:  2019-08-20       Impact factor: 4.207

4.  Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment.

Authors:  Hao Wang; Sha Zhao; Xiaoshen Zhang; Keyi Jia; Juan Deng; Caicun Zhou; Yayi He
Journal:  Onco Targets Ther       Date:  2019-09-05       Impact factor: 4.147

5.  Cancer and Autoimmune Diseases: A Tale of Two Immunological Opposites?

Authors:  Zeev Elkoshi
Journal:  Front Immunol       Date:  2022-01-25       Impact factor: 7.561

6.  Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I-III small cell lung cancer.

Authors:  Peixin Chen; Lishu Zhao; Hao Wang; Liping Zhang; Wei Zhang; Jun Zhu; Jia Yu; Sha Zhao; Wei Li; Chenglong Sun; Chunyan Wu; Yayi He; Caicun Zhou
Journal:  J Immunother Cancer       Date:  2021-08       Impact factor: 13.751

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.